Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral ...
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company at the forefront of precision genetic medicines with a market capitalization of $1.87 billion, is navigating a critical juncture in its ...